Published on
October 30, 2019
- 20:00 GMT
Immunomedics Reports Third Quarter 2019 Results and Provides Corporate Update
TROPHY-U-01 Reached Target Enrollment in Cisplatin-Eligible Cohort of 100 Patients First NSCLC Patient Dosed in Trop-2-Enriched TROPiCS-03 Study BLA Resubmission Targeted for Late November/Early December 2019 MORRIS PLAINS, N.J., Oct. 30, 2019 (GLOBE …
Distribution channels:
Business & Economy, Technology
...
